- Home
- SPPP vs NTHI Comparison
SPPP vs NTHI Comparison
Compare SPPP & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPPP
- NTHI
- Stock Information
- Founded
- SPPP 2011
- NTHI 2008
- Country
- SPPP Canada
- NTHI United States
- Employees
- SPPP N/A
- NTHI N/A
- Industry
- SPPP
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- SPPP
- NTHI Health Care
- Exchange
- SPPP NYSE
- NTHI Nasdaq
- Market Cap
- SPPP 172.2M
- NTHI 142.5M
- IPO Year
- SPPP N/A
- NTHI N/A
- Fundamental
- Price
- SPPP $10.33
- NTHI $7.39
- Analyst Decision
- SPPP
- NTHI
- Analyst Count
- SPPP 0
- NTHI 0
- Target Price
- SPPP N/A
- NTHI N/A
- AVG Volume (30 Days)
- SPPP 183.3K
- NTHI 93.9K
- Earning Date
- SPPP 01-01-0001
- NTHI 01-01-0001
- Dividend Yield
- SPPP N/A
- NTHI N/A
- EPS Growth
- SPPP N/A
- NTHI N/A
- EPS
- SPPP N/A
- NTHI N/A
- Revenue
- SPPP N/A
- NTHI $79,990.00
- Revenue This Year
- SPPP N/A
- NTHI N/A
- Revenue Next Year
- SPPP N/A
- NTHI N/A
- P/E Ratio
- SPPP N/A
- NTHI N/A
- Revenue Growth
- SPPP N/A
- NTHI 13.52
- 52 Week Low
- SPPP $8.55
- NTHI $4.11
- 52 Week High
- SPPP $11.39
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- SPPP 65.99
- NTHI N/A
- Support Level
- SPPP $10.05
- NTHI N/A
- Resistance Level
- SPPP $10.25
- NTHI N/A
- Average True Range (ATR)
- SPPP 0.13
- NTHI 0.00
- MACD
- SPPP 0.03
- NTHI 0.00
- Stochastic Oscillator
- SPPP 87.46
- NTHI 0.00
About SPPP SPROTT PHYS PLATINUM & PALLADIUM
Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").